Integral Health Asset Management, LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Integral Health Asset Management, LLC reported 69 stock positions worth $1.0 billion. Its top holding was Insmed (INSM) at 10.3% of the portfolio, followed by Tenet Healthcare (THC, 6.6%) and Cytokinetics (CYTK, 5.4%). Compared with Q1 2024, it opened 22 new positions, sold out of 29, added to 29 and reduced 11. The biggest buy was Insmed (INSM, shares +19%) and the biggest sale an exit from Walgreens Boots Alliance (WBA).
- Most Recent 13F
- Q2 2026
- Location
- New York, NY
- CIK
- 0001773206
- Portfolio Value
- $1.0B (Q2 2024)
- SEC Filing
- 0001172661-24-003360 ↗ filed Aug 14, 2024
Holdings Value
Holdings 69 stocks · $1.0B
| INSM Insmed Inc. | 10.34% | 1,550,000 | $103.8M | Add +19.2% |
| THC Tenet Healthcare Corp. | 6.62% | 500,000 | $66.5M | Add +17.6% |
| CYTK Cytokinetics Inc. | 5.39% | 1,000,000 | $54.2M | Add +122.2% |
| BSX Boston Scientific Corp. | 4.98% | 650,000 | $50.1M | Add +8.3% |
| ELV Elevance Health Inc. | 4.31% | 80,000 | $43.3M | Add +60.0% |
| BPMC Blueprint Medicines Corp. | 3.65% | 340,000 | $36.6M | Add +61.9% |
| NVS Novartis AG-Sponsored ADR | 3.18% | 300,000 | $31.9M | Add +33.3% |
| LBPH Longboard Pharmaceuticals Inc. | 2.96% | 1,100,000 | $29.7M | Add +12.8% |
| MRK Merck & Co. Inc. | 2.90% | 235,000 | $29.1M | No change |
| HUM Humana Inc. | 2.79% | 75,000 | $28.0M | Add +25.0% |
| EHC Encompass Health Corp. | 2.56% | 300,000 | $25.7M | Reduce -14.3% |
| UHS Universal Health Services-B | 2.39% | 130,000 | $24.0M | Add +4.0% |
| NARI Inari Medical Inc. | 1.92% | 400,000 | $19.3M | Add +100.0% |
| VERA Vera Therapeutics Inc. | 1.80% | 500,000 | $18.1M | Add +38.9% |
| CRNX Crinetics Pharmaceuticals Inc. | 1.78% | 400,000 | $17.9M | Add +23.1% |
| BDX Becton Dickinson and Co. | 1.74% | 75,000 | $17.5M | New |
| CI The Cigna Group | 1.65% | 50,000 | $16.5M | Add +25.0% |
| TARS Tarsus Pharmaceuticals Inc. | 1.60% | 590,000 | $16.0M | No change |
| KRYS Krystal Biotech Inc. | 1.55% | 85,000 | $15.6M | Add +6.3% |
| ACLX Arcellx Inc. | 1.51% | 275,000 | $15.2M | Add +7.8% |
| ICLR Icon PLC | 1.40% | 45,000 | $14.1M | No change |
| EW Edwards Lifesciences Corp. | 1.38% | 150,000 | $13.9M | New |
| TMO Thermo Fisher Scientific Inc. | 1.38% | 25,000 | $13.8M | New |
| DGX Quest Diagnostics Inc. | 1.36% | 100,000 | $13.7M | New |
| VKTX Viking Therapeutics Inc. | 1.32% | 250,000 | $13.3M | Reduce -44.4% |
| RVMD Revolution Medicines Inc. | 1.26% | 325,000 | $12.6M | Reduce -22.6% |
| AMGN Amgen Inc. | 1.24% | 40,000 | $12.5M | New |
| IONS Ionis Pharmaceuticals Inc. | 1.19% | 250,000 | $11.9M | New |
| MCK McKesson Corp. | 1.16% | 20,000 | $11.7M | New |
| RGNX Regenxbio Inc. | 1.11% | 950,000 | $11.1M | Add +25.0% |
| ITCI Intra-Cellular Therapies Inc. | 0.99% | 145,000 | $9.9M | Add +16.0% |
| SNY Sanofi-ADR | 0.97% | 200,000 | $9.7M | New |
| MLTX Moonlake Immunotherapeutics | 0.96% | 220,000 | $9.7M | No change |
| NBIX Neurocrine Biosciences Inc. | 0.96% | 70,000 | $9.6M | Reduce -53.3% |
| TFX Teleflex Inc. | 0.94% | 45,000 | $9.5M | New |
| LLY Eli Lilly & Co. | 0.90% | 10,000 | $9.1M | Reduce -16.7% |
| GMED Globus Medical Inc. Class A | 0.85% | 125,000 | $8.6M | New |
| BRKR Bruker Corp. | 0.83% | 130,000 | $8.3M | Reduce -40.9% |
| CRSP Crispr Therapeutics AG | 0.81% | 150,000 | $8.1M | Reduce -31.8% |
| OSCR Oscar Health Inc. Class A | 0.79% | 500,000 | $7.9M | No change |
| RGEN Repligen Corp. | 0.75% | 60,000 | $7.6M | Add +20.0% |
| DNLI Denali Therapeutics Inc. | 0.75% | 325,000 | $7.5M | New |
| TNYA Tenaya Therapeutics Inc. | 0.72% | 2,325,000 | $7.2M | Add +3.3% |
| SANA Sana Biotechnology Inc. | 0.65% | 1,200,000 | $6.6M | Add +22.4% |
| ELAN Elanco Animal Health Inc. | 0.65% | 450,000 | $6.5M | Reduce -18.2% |
| MREO Mereo Biopharma Group PL-ADR | 0.64% | 1,775,000 | $6.4M | Add +86.8% |
| MRUS Merus NV | 0.59% | 100,000 | $5.9M | Reduce -39.4% |
| PODD Insulet Corp. | 0.50% | 25,000 | $5.0M | New |
| QDEL Quidelortho Corp. | 0.50% | 150,000 | $5.0M | New |
| RLAY Relay Therapeutics Inc. | 0.49% | 750,000 | $4.9M | Add +3.5% |
| SGRY Surgery Partners Inc. | 0.47% | 200,000 | $4.8M | New |
| CRBP Corbus Pharmaceuticals Holdi | 0.45% | 100,000 | $4.5M | New |
| ISRG Intuitive Surgical Inc. | 0.44% | 10,000 | $4.4M | Reduce -80.0% |
| CPRX Catalyst Pharmaceuticals Inc. | 0.42% | 275,000 | $4.3M | New |
| ROIV Roivant Sciences Ltd. | 0.42% | 400,000 | $4.2M | Reduce -33.3% |
| KROS Keros Therapeutics Inc. | 0.39% | 85,000 | $3.9M | Add +112.5% |
| HOLX Hologic Inc. | 0.37% | 50,000 | $3.7M | New |
| ETNB 89BIO Inc. | 0.36% | 450,000 | $3.6M | Add +50.0% |
| DYN Dyne Therapeutics Inc. | 0.35% | 100,000 | $3.5M | New |
| SRRK Scholar Rock Holding Corp. | 0.33% | 400,000 | $3.3M | Add +23.1% |
| CABA Cabaletta Bio Inc. | 0.32% | 425,000 | $3.2M | No change |
| EDIT Editas Medicine Inc. | 0.31% | 675,000 | $3.2M | Add +50.0% |
| APGE Apogee Therapeutics Inc. | 0.31% | 80,000 | $3.1M | Add +100.0% |
| NRIX Nurix Therapeutics Inc. | 0.31% | 150,000 | $3.1M | New |
| FATE Fate Therapeutics Inc. | 0.28% | 850,000 | $2.8M | Add +325.0% |
| NGNE Neurogene Inc. | 0.25% | 70,000 | $2.5M | New |
| SYRE Spyre Therapeutics Inc. | 0.23% | 100,000 | $2.4M | No change |
| KURA Kura Oncology Inc. | 0.20% | 100,000 | $2.1M | New |
| RVNC Revance Therapeutics Inc. | 0.13% | 500,000 | $1.3M | New |
Options reported separately and not counted above: IONS calls ($23.8M), VKTX calls ($13.3M), TARS puts ($10.9M).
Portfolio Sells Q1 2024 → Q2 2024
| WBA Walgreens Boots Alliance Inc. | Sold out | 0.00% | −2.77 |
| ABBV Abbvie Inc. | Sold out | 0.00% | −2.41 |
| VKTX Viking Therapeutics Inc. | Reduce -44.4% | 1.32% | −2.30 |
| CRL Charles River Laboratories | Sold out | 0.00% | −1.73 |
| REGN Regeneron Pharmaceuticals | Sold out | 0.00% | −1.61 |
| PEN Penumbra Inc. | Sold out | 0.00% | −1.53 |
| ISRG Intuitive Surgical Inc. | Reduce -80.0% | 0.44% | −1.52 |
| DXCM Dexcom Inc. | Sold out | 0.00% | −1.36 |
| SWAV Shockwave Medical Inc. | Sold out | 0.00% | −1.28 |
| AVTR Avantor Inc. | Sold out | 0.00% | −1.25 |
| BRKR Bruker Corp. | Reduce -40.9% | 0.83% | −1.20 |
| COR Cencora Inc. | Sold out | 0.00% | −1.19 |
| COO The Cooper Cos Inc. | Sold out | 0.00% | −1.10 |
| NBIX Neurocrine Biosciences Inc. | Reduce -53.3% | 0.96% | −1.07 |
| ALPN Alpine Immune Sciences Inc. | Sold out | 0.00% | −0.90 |
| APLS Apellis Pharmaceuticals Inc. | Sold out | 0.00% | −0.87 |
| EVH Evolent Health Inc. Class A | Sold out | 0.00% | −0.80 |
| TNDM Tandem Diabetes Care Inc. | Sold out | 0.00% | −0.78 |
| FDMT 4D Molecular Therapeutics Inc. | Sold out | 0.00% | −0.78 |
| ALNY Alnylam Pharmaceuticals Inc. | Sold out | 0.00% | −0.73 |
| MGNX Macrogenics Inc. | Sold out | 0.00% | −0.72 |
| INSP Inspire Medical Systems Inc. | Sold out | 0.00% | −0.70 |
| CRSP Crispr Therapeutics AG | Reduce -31.8% | 0.81% | −0.67 |
| ALKS Alkermes PLC | Sold out | 0.00% | −0.66 |
| ONC Beone Medicines Ltd.-ADR | Sold out | 0.00% | −0.61 |
| RVTY Revvity Inc. | Sold out | 0.00% | −0.52 |
| ALGN Align Technology Inc. | Sold out | 0.00% | −0.48 |
| NTRA Natera Inc. | Sold out | 0.00% | −0.45 |
| LH Laboratory CRP of Amer Hldgs | Sold out | 0.00% | −0.43 |
| A Agilent Technologies Inc. | Sold out | 0.00% | −0.43 |
| SAGE Sage Therapeutics Inc. | Sold out | 0.00% | −0.37 |
| AUTL Autolus Therapeutics PLC | Sold out | 0.00% | −0.31 |
| GH Guardant Health Inc. | Sold out | 0.00% | −0.30 |
| EHC Encompass Health Corp. | Reduce -14.3% | 2.56% | −0.28 |
| AXSM Axsome Therapeutics Inc. | Sold out | 0.00% | −0.23 |
| ELAN Elanco Animal Health Inc. | Reduce -18.2% | 0.65% | −0.23 |
| ROIV Roivant Sciences Ltd. | Reduce -33.3% | 0.42% | −0.20 |
| MRUS Merus NV | Reduce -39.4% | 0.59% | −0.14 |
| RVMD Revolution Medicines Inc. | Reduce -22.6% | 1.26% | −0.07 |
| LLY Eli Lilly & Co. | Reduce -16.7% | 0.90% | −0.02 |
Portfolio Buys Q1 2024 → Q2 2024
| INSM Insmed Inc. | Add +19.2% | 10.34% | +6.87 |
| CYTK Cytokinetics Inc. | Add +122.2% | 5.39% | +2.30 |
| THC Tenet Healthcare Corp. | Add +17.6% | 6.62% | +2.24 |
| ELV Elevance Health Inc. | Add +60.0% | 4.31% | +1.77 |
| BDX Becton Dickinson and Co. | New | 1.74% | +1.74 |
| BPMC Blueprint Medicines Corp. | Add +61.9% | 3.65% | +1.69 |
| EW Edwards Lifesciences Corp. | New | 1.38% | +1.38 |
| TMO Thermo Fisher Scientific Inc. | New | 1.38% | +1.38 |
| DGX Quest Diagnostics Inc. | New | 1.36% | +1.36 |
| AMGN Amgen Inc. | New | 1.24% | +1.24 |
| IONS Ionis Pharmaceuticals Inc. | New | 1.19% | +1.19 |
| MCK McKesson Corp. | New | 1.16% | +1.16 |
| NVS Novartis AG-Sponsored ADR | Add +33.3% | 3.18% | +1.04 |
| NARI Inari Medical Inc. | Add +100.0% | 1.92% | +0.97 |
| SNY Sanofi-ADR | New | 0.97% | +0.97 |
| BSX Boston Scientific Corp. | Add +8.3% | 4.98% | +0.95 |
| TFX Teleflex Inc. | New | 0.94% | +0.94 |
| LBPH Longboard Pharmaceuticals Inc. | Add +12.8% | 2.96% | +0.89 |
| GMED Globus Medical Inc. Class A | New | 0.85% | +0.85 |
| DNLI Denali Therapeutics Inc. | New | 0.75% | +0.75 |
| HUM Humana Inc. | Add +25.0% | 2.79% | +0.75 |
| PODD Insulet Corp. | New | 0.50% | +0.50 |
| QDEL Quidelortho Corp. | New | 0.50% | +0.50 |
| SGRY Surgery Partners Inc. | New | 0.47% | +0.47 |
| CRBP Corbus Pharmaceuticals Holdi | New | 0.45% | +0.45 |
| CPRX Catalyst Pharmaceuticals Inc. | New | 0.42% | +0.42 |
| HOLX Hologic Inc. | New | 0.37% | +0.37 |
| DYN Dyne Therapeutics Inc. | New | 0.35% | +0.35 |
| MREO Mereo Biopharma Group PL-ADR | Add +86.8% | 0.64% | +0.33 |
| NRIX Nurix Therapeutics Inc. | New | 0.31% | +0.31 |
| CRNX Crinetics Pharmaceuticals Inc. | Add +23.1% | 1.78% | +0.29 |
| VERA Vera Therapeutics Inc. | Add +38.9% | 1.80% | +0.28 |
| NGNE Neurogene Inc. | New | 0.25% | +0.25 |
| CI The Cigna Group | Add +25.0% | 1.65% | +0.22 |
| KURA Kura Oncology Inc. | New | 0.20% | +0.20 |
| KRYS Krystal Biotech Inc. | Add +6.3% | 1.55% | +0.16 |
| UHS Universal Health Services-B | Add +4.0% | 2.39% | +0.15 |
| ITCI Intra-Cellular Therapies Inc. | Add +16.0% | 0.99% | +0.14 |
| FATE Fate Therapeutics Inc. | Add +325.0% | 0.28% | +0.13 |
| RVNC Revance Therapeutics Inc. | New | 0.13% | +0.13 |
| KROS Keros Therapeutics Inc. | Add +112.5% | 0.39% | +0.13 |
| APGE Apogee Therapeutics Inc. | Add +100.0% | 0.31% | +0.05 |
| ETNB 89BIO Inc. | Add +50.0% | 0.36% | +0.02 |
| EDIT Editas Medicine Inc. | Add +50.0% | 0.31% | −0.01 |
| RLAY Relay Therapeutics Inc. | Add +3.5% | 0.49% | −0.10 |
| RGEN Repligen Corp. | Add +20.0% | 0.75% | −0.15 |
| ACLX Arcellx Inc. | Add +7.8% | 1.51% | −0.23 |
| SRRK Scholar Rock Holding Corp. | Add +23.1% | 0.33% | −0.23 |
| SANA Sana Biotechnology Inc. | Add +22.4% | 0.65% | −0.31 |
| TNYA Tenaya Therapeutics Inc. | Add +3.3% | 0.72% | −0.44 |
Options Activity Q1 2024 → Q2 2024
| VKTX Viking Therapeutics Inc. | put | Sold out | 300,000 | $24.6Mbefore exit |
| IONS Ionis Pharmaceuticals Inc. | call | New | 500,000 | $23.8M |
| INSM Insmed Inc. | call | Sold out | 500,000 | $13.6Mbefore exit |
| VKTX Viking Therapeutics Inc. | call | New | 250,000 | $13.3M |
| TARS Tarsus Pharmaceuticals Inc. | put | New | 400,000 | $10.9M |
| EXAS Exact Sciences Corp. | call | Sold out | 150,000 | $10.4Mbefore exit |
| MLTX Moonlake Immunotherapeutics | call | Sold out | 200,000 | $10.0Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 89 | $2.4B | RVMD, INSM, CYTK, CVS, EWTX |
| Q1 2026 | 86 | $1.9B | INSM, RVMD, CYTK, REGN, VERA |
| Q4 2025 | 84 | $2.0B | INSM, RVMD, VERA, CYTK, REGN |
| Q3 2025 | 72 | $1.4B | INSM, CYTK, THC, MLYS, VERA |
| Q2 2025 | 70 | $1.1B | INSM, BSX, THC, EHC, MLYS |
| Q1 2025 | 76 | $902.7M | INSM, BSX, CYTK, THC, MLYS |
| Q4 2024 | 81 | $1.1B | INSM, THC, BSX, VERA, CYTK |
| Q3 2024 | 63 | $849.4M | INSM, THC, BSX, CYTK, LBPH |
| Q2 2024 | 69 | $1.0B | INSM, THC, CYTK, BSX, ELV |
| Q1 2024 | 76 | $1.0B | THC, BSX, VKTX, INSM, CYTK |